GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2012

Merck Serono Begins Job Creation Process

  • Merck Serono, a division of Merck, has created Prexton Therapeutics, the first spin-off company resulting from its Entrepreneur Partnership Program launched in April. Prexton Therapeutics will be formed around Merck Serono’s R&D portfolio in the field of Parkinson’s disease and will focus on programs that target the metabotropic glutamate receptors mGluR3 and mGluR4.

    Prexton will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development. Merck Serono will invest €2.1 million as seed funding. Merck Serono Ventures will manage the investment and will be represented on the company’s board of directors.

    “Metabotropic glutamate receptors (mGluR) have been shown recently to be a key target to tackle the onset of Parkinson’s disease. Therefore, modulating their response is certainly among the most promising ways to develop future treatments for one of the most severe brain diseases,” said François Conquet, founder and CEO of Prexton Therapeutics.

    Announced in April in the framework of the efficiency measures being taken by Merck Serono, the Entrepreneur Partnership Program is part of a €30 million commitment to support the creation of spin-off and startup companies focused on continuing activities and compounds that originated at Merck Serono.

    This program is aimed at reducing the impact on employment following closure of the Geneva headquarters due to restructuring. In April, Merck Serono said that 500 jobs would likely be cut, but over 750 would be transferred. For details on the firm’s restructuring, click here.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?